While HER2-targeted therapies improve outcomes for patients with HER2-amplified breast cancers, resistance to HER2 inhibitors often occurs, underscoring the need for increased understanding of the signaling pathways required for HER2-mediated transformation and malignancy. Here, ERBB2 is linked to breast cancer.